”We plan to have a fully certified product on the market by 2023, but the method is already being tested in healthcare for use as soon as possible”, says Linus Bosaeus, new CEO of Rarity Bioscience AB in interview on Uppsala University Invest.
Read the full article at https://uuinvest.se/precisionsdiagnstik-i-fokus-for-rarity-bioscience/
(Article in Swedish)
